4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

June 2, 2026 updated by: Ardelyx

4-Week, Multi-Center, Randomized, Db-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety & Efficacy of Tenapanor for the T/t of IBS-C in Pts. 6 to < 12 Yrs. Old

This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study consists of 2 week screening period in which subjects who have consented will be evaluated for eligibility per protocol requirements. During this 2 week screening period subjects will be given access to ediary in which they will be required to self report symptoms of IBS-C daily. Information in ediary will also be used to determine eligibility prior to enrollment.

During the 4 week RTP (Randomized treatment period), subjects will be randomized in in a ratio of 5:1 to receive tenapanor or matching placebo for 4 weeks. During the RTP, patients will continue recording daily assessments in the eDiary system as instructed and compliance with eDiary entries will be monitored. Patients will return for study visit every weeks (Visits 3-6) and will undergo safety assessments as per the protocol. At the end of this 4 week period, subjects will complete 2 week treatment free follow-up period and safety assessments per protocol will be conducted at the end of this 2 week period.

The study plans to enroll up to 6 cohorts of eligible patients sequentially, starting from Cohort 1 with 12 patients randomized in to receive tenapanor 2 mg BID or matching placebo for 4 weeks. Subsequent cohorts will assess increasing tenapanor doses, following a dose escalation order. The study will proceed to the next dosing cohort if the current cohort completes the 4-week RTP and does not meet any of the dose escalation stopping criteria pre-specified in the protocol.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
72

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Applied Research Center of Arkansas
    • Connecticut
      • Hartford, Connecticut, United States, 06106
        • Connecticut Children's Medical Center
    • Florida
      • Miami, Florida, United States, 33165
        • Valencia Medical and Research Center
      • Miami, Florida, United States, 33155
        • Waterway Research & Associates Corp.
      • Orlando, Florida, United States, 32806
        • Orlando Health, Inc.- APH Center for Digestive Health and Nutrition
      • South Miami, Florida, United States, 33143
        • Florida Pharmaceutical Research and Associates, Inc.
    • Illinois
      • Peoria, Illinois, United States, 61637
        • OSF Saint Francis Medical Center
    • Minnesota
      • Mankato, Minnesota, United States, 56001
        • Mankato Clinic Children's Health Center
    • Nebraska
      • Boys Town, Nebraska, United States, 68010
        • Boys Town National Research Hospital
    • New York
      • Brooklyn, New York, United States, 11203
        • SUNY Downstate Medical Center
    • North Carolina
      • Wilmington, North Carolina, United States, 28401
        • Wilmington Health
    • Ohio
      • Akron, Ohio, United States, 44308
        • Akron Children's Hospital
    • South Carolina
      • Greenville, South Carolina, United States, 29615
        • Prisma Health Children's Hospital
    • Texas
      • El Paso, Texas, United States, 79902
        • Maspons Pediatric Gastro
      • El Paso, Texas, United States, 79902
        • Proactive El Paso, LLC
      • Harlingen, Texas, United States, 78550
        • Texas Digestive Specialists
      • San Antonio, Texas, United States, 78215
        • Sun Research Institute
      • Sugar Land, Texas, United States, 77479
        • Pioneer Research Solutions Inc
    • Virginia
      • Richmond, Virginia, United States, 23226
        • Clinical Research Partners, LLC
    • West Virginia
      • Huntington, West Virginia, United States, 25701
        • University Physicians and Surgeons, Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. ≥6 and <12 years old at the Screening visit (Visit 1)
  2. Confirmation of negative pregnancy test and use of appropriate contraceptive (including abstinence) in female subjects that have experienced menarche and are of child-bearing potential.
  3. Meet the Modified Diagnostic Rome IV criteria for child/adolescent diagnosis of IBS-C
  4. Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
  5. Meet the entry criteria assessed during the 2-week Screening period
  6. Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
  7. Patient must provide verbal assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures

Exclusion Criteria:

  1. Functional diarrhea as defined by Modified Rome IV child/adolescent criteria
  2. IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Modified Rome IV child/adolescent criteria
  3. History of non-retentive fecal incontinence;
  4. Required manual disimpaction any time prior to randomization (after consent)
  5. Currently has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process.

  6. Patient has any of the following conditions:

    1. Celiac disease, or positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy;
    2. Cystic fibrosis;
    3. Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to the Screening Visit;
    4. Down's syndrome or any other chromosomal disorder;
    5. Active anal fissure (Note: History of anal fissure is not an exclusion);
    6. Anatomic malformations (eg, imperforate anus, anal stenosis, anterior displaced anus);
    7. Intestinal nerve or muscle disorders (eg, Hirschprung disease, visceral myopathies, visceral neuropathies);
    8. Neuropathic conditions (eg, spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma);
    9. Lead toxicity, hypercalcemia;
    10. Neurodevelopmental disabilities
    11. Inflammatory bowel disease
    12. Childhood functional abdominal pain syndrome
    13. Childhood functional abdominal pain
    14. Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
    15. Lactose intolerance that is associated with abdominal pain or discomfort and could confound the assessments in this study
    16. History of cancer other than treated basal cell carcinoma of the skin;
    17. History of diabetic neuropathy.
  7. Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.

  8. Patient has had surgery that meets any of the following criteria:

    1. Surgery to remove a segment of the GI tract at any time before the Screening Visit;
    2. Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
    3. An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
    4. Other major surgery during the 30 days before the Screening Visit
  9. History of alcohol or substance abuse
  10. Participation in other clinical trials within 1 month prior to Screening
  11. Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial
  12. If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Matching placebo
Drug: Placebo
Matching Placebo solution
Experimental: Tenapanor Cohort 1
Tenapanor 2 mg BID
Drug: Tenapanor
Tenapanor 5 mg/mL solution
Other Names:
  • IBSRELA
Experimental: Tenapanor Cohort 2
Tenapanor 5 mg BID
Drug: Tenapanor
Tenapanor 5 mg/mL solution
Other Names:
  • IBSRELA
Experimental: Tenapanor Cohort 3
Tenapanor 10 mg BID
Drug: Tenapanor
Tenapanor 5 mg/mL solution
Other Names:
  • IBSRELA
Experimental: Tenapanor Cohort 4
Tenapanor 15 mg BID
Drug: Tenapanor
Tenapanor 5 mg/mL solution
Other Names:
  • IBSRELA
Experimental: Tenapanor Cohort 5
Tenapanor 20 mg BID
Drug: Tenapanor
Tenapanor 5 mg/mL solution
Other Names:
  • IBSRELA
Experimental: Tenapanor Cohort 6
Tenapanor 25 mg BID
Drug: Tenapanor
Tenapanor 5 mg/mL solution
Other Names:
  • IBSRELA

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Average weekly SBM (week 4)
Time Frame: 4 weeks
Change from baseline in average weekly SBM frequency in Week 4
4 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Average weekly SBM (weeks 1, 2 and 3)
Time Frame: 3 weeks
Change from baseline in average weekly SBM frequency in Week 1, Week 2, and Week 3
3 weeks
SBM Response
Time Frame: 6 weeks
Weekly ≥3 SBM response: achieving an average weekly SBM frequency ≥3 for a given week
6 weeks
Rescue medication
Time Frame: 6 weeks
Overall use of rescue medication
6 weeks
Stool consistency
Time Frame: 6 weeks

Percent change from baseline in average weekly stool consistency score in each week

Scale Range:

  1. one (1)= Rabbit droppings: separate hard lumps, like nuts (hard to pass)
  2. seven (7) for Gravy: watery, no solids pieces, entirely liquid"
6 weeks
Abdominal Pain Score
Time Frame: 6 weeks

Percent change from baseline in average weekly abdominal pain score in each week

Scale Range:

zero (0) = no pain and ten (10)= very severe abdominal pain
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ardelyx

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Jocelyn Tabora, Ardelyx

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 24, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 14, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TEN-01-202

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Irritable Bowel Syndrome With Constipation (IBS-C)

Clinical Trials on Tenapanor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings